Compare Acadia Healthcare Company Inc (ACHC) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Bristol-Myers Squibb Co — how do they compare? Acadia Healthcare Company Inc trades at $31.86 (market cap $2.90B), while Bristol-Myers Squibb Co trades at $63.75 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 44.8× Acadia Healthcare Company Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | BMY | |
|---|---|---|
Market Cap | $2.90B | $129.94B |
Sector | Health | Health |
52-Week High | $35.61 | $65.89 |
52-Week Low | $11.68 | $42.60 |
Enterprise Value | $5.29B | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.85, up 0.22% today, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 EPS of $0.38, beating estimates, but maintains negative net income margins near -33%. Revenue is stable at $3.3B, while analyst consensus is a Buy with a $36 price target. Recent news highlights ongoing litigation and operational progress.
Outlook is mixed: strong analyst support and earnings beats suggest upside, but profitability challenges and legal investigations pose significant risks. The stock's valuation appears reasonable with a P/E of 19.82, yet negative ROE and net income require careful monitoring for turnaround execution.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
